Sign in
4

Changes in Ownership

CORCEPT THERAPEUTICS INC Filed Acc 0001193125-26-308058

Chief Financial Officer sold 40,000 shares at an average $87.71 ($3,508,277)

  • Chief Financial Officer acquired 40,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Mokari Atabak · Chief Financial Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2026-07-15 Exercise or conversion : show line 1 in the form 10b5-1 +15,833 $19.26 $304,944 31,963 D
2026-07-15 Exercise or conversion : show line 2 in the form 10b5-1 +24,167 $23.06 $557,291 56,130 D
2026-07-15 Sale : show line 3 in the form 10b5-1 −7,919 $86.78 $687,179 48,211 D
2026-07-15 Sale : show line 4 in the form 10b5-1 −28,460 $87.89 $2,501,244 19,751 D
2026-07-15 Sale : show line 5 in the form 10b5-1 −3,520 $88.30 $310,822 16,231 D
2026-07-15 Sale : show line 6 in the form 10b5-1 −101 $89.43 $9,032 16,130 D
Open-market sales · 40,000 sh · avg $87.71 · $3,508,277

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-07-15 Exercise or conversion : show line 7 in the form 10b5-1 Stock option (right to buy) −15,833 4,167 D
2026-07-15 Exercise or conversion : show line 8 in the form 10b5-1 Stock option (right to buy) −24,167 175,833 D
Loading xslF345X06/ownership.xml…